| フルテキストURL | J_Thorac_Oncol_201907017.pdf |
|---|---|
| 著者 | Makimoto, Go| Ohashi, Kadoaki| Tomida, Shuta| Nishii, Kazuya| Matsubara, Takehiro| Kayatani, Hiroe| Higo, Hisao| Ninomiya, Kiichiro| Sato, Akiko| Watanabe, Hiromi| Kano, Hirohisa| Ninomiya, Takashi| Kubo, Toshio| Rai, Kammei| Ichihara, Eiki| Hotta, Katsuyuki| Tabata, Masahiro| Toyooka, Shinichi| Takata, Minoru| Maeda, Yoshinobu| Kiura, Katsuyuki| |
| キーワード | ALK G1202R Alectinib Amphiregulin MET NSCLC |
| 発行日 | 2019-07-30 |
| 出版物タイトル | Journal of Thoracic Oncology |
| 巻 | 14巻 |
| 号 | 11号 |
| 出版者 | Elsevier |
| 開始ページ | 2009 |
| 終了ページ | 2018 |
| ISSN | 15560864 |
| NCID | AA12058455 |
| 資料タイプ | 学術雑誌論文 |
| 言語 | 英語 |
| OAI-PMH Set | 岡山大学 |
| 著作権者 | © 2019 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved. |
| 論文のバージョン | author |
| PubMed ID | 31374369 |
| DOI | 10.1016/j.jtho.2019.07.017 |
| Web of Science KeyUT | 000492678300025 |
| 関連URL | isVersionOf https://doi.org/10.1016/j.jtho.2019.07.017 |
| JaLCDOI | 10.18926/AMO/55446 |
|---|---|
| フルテキストURL | 71_5_453.pdf |
| 著者 | Taniguchi, Akihiko| Miyahara, Nobuaki| Oda, Naohiro| Morichika, Daisuke| Ichihara, Eiki| Oze, Isao| Tanimoto, Yasushi| Ichikawa, Hirohisa| Fujii, Utako| Tanimoto, Mitsune| Kanehiro, Arihiko| Kiura, Katsuyuki| |
| 抄録 | Although recent retrospective studies suggested that the use of β-blockers appears to help improve the mortality rate and decrease the rate of exacerbation in chronic obstructive pulmonary disease (COPD) patients with heart failure, the effects of β-blockers on COPD patients without heart failure have not been established. Based on previous reports, we have launched a multicenter, prospective, single-arm phase II study to evaluate the preventive effect of the cardioselective β-blocker bisoprolol in COPD exacerbation, in Japanese individuals with moderate-to-severe COPD who do not have heart failure but do have hypertension requiring the use of medication. The primary endpoint is the rate of mild-to-severe COPD exacerbation. The results of this study will clarify whether bisoprolol can prevent exacerbation in COPD patients without heart failure. |
| キーワード | chronic obstructive pulmonary disease β-blocker bisoprolol exacerbation heart failure |
| Amo Type | Clinical Study Protocol |
| 出版物タイトル | Acta Medica Okayama |
| 発行日 | 2017-10 |
| 巻 | 71巻 |
| 号 | 5号 |
| 出版者 | Okayama University Medical School |
| 開始ページ | 453 |
| 終了ページ | 457 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| 資料タイプ | 学術雑誌論文 |
| 言語 | 英語 |
| 著作権者 | CopyrightⒸ 2017 by Okayama University Medical School |
| 論文のバージョン | publisher |
| 査読 | 有り |
| PubMed ID | 29042706 |
| JaLCDOI | 10.18926/AMO/54499 |
|---|---|
| フルテキストURL | 70_4_243.pdf |
| 著者 | Osawa, Masahiro| Ohashi, Kadoaki| Kubo, Toshio| Ichihara, Eiki| Takata, Saburo| Takigawa, Nagio| Takata , Minoru| Tanimoto, Mitsune| Kiura, Katsuyuki| |
| 抄録 | Vandetanib (ZactimaTM) is a novel, orally available inhibitor of both vascular endothelial growth factor receptor-2 (VEGFR-2) and epidermal growth factor receptor (EGFR) tyrosine kinase. In the present study, a line of transgenic mice with a mouse Egfr gene mutation (delE748-A752) corresponding to a human EGFR mutation (delE746-A750) was established. The transgenic mice developed atypical adenomatous hyperplasia to adenocarcinoma of the lung at around 5 weeks of age and died of lung tumors at approximately 17 weeks of age. In the mice treated with vandetanib (6mg/kg/day), these lung tumors disappeared and the phosphorylations of EGFR and VEGFR-2 were reduced in lung tissues to levels comparable to those of non-transgenic control mice. The median overall survival time of the transgenic mice was 28 weeks in the vandetanib-treated group and 17 weeks in the vehicle-treated group. Vandetanib significantly prolonged the survival of the transgenic mice (log-rank test, p＜0.01); resistance to vandetanib occurred at 20 weeks of age and the animals died from their lung tumors at about 28 weeks of age. These data suggest that vandetanib could suppress the progression of tumors harboring an activating EGFR mutation. |
| キーワード | vandetanib VEGFR EGFR nonsmall cell lung cancer transgenic mouse |
| Amo Type | Original Article |
| 出版物タイトル | Acta Medica Okayama |
| 発行日 | 2016-08 |
| 巻 | 70巻 |
| 号 | 4号 |
| 出版者 | Okayama University Medical School |
| 開始ページ | 243 |
| 終了ページ | 253 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| 資料タイプ | 学術雑誌論文 |
| 言語 | 英語 |
| 著作権者 | CopyrightⒸ 2016 by Okayama University Medical School |
| 論文のバージョン | publisher |
| 査読 | 有り |
| PubMed ID | 27549668 |
| Web of Science KeyUT | 000384748600003 |
| 著者 | Harada, Daijiro| Takigawa, Nagio| Ochi, Nobuaki| Ninomiya, Takashi| Yasugi, Masayuki| Kubo, Toshio| Takeda, Hiromasa| Ichihara, Eiki| Ohashi, Kadoaki| Takata, Saburo| Tanimoto, Mitsune| Kiura, Katsuyuki| |
|---|---|
| 発行日 | 2012-10 |
| 出版物タイトル | Cancer Science |
| 巻 | 103巻 |
| 号 | 10号 |
| 資料タイプ | 学術雑誌論文 |
| 著者 | Kubo, Toshio| Takigawa, Nagio| Osawa, Masahiro| Harada, Daijiro| Ninomiya, Takashi| Ochi, Nobuaki| Ichihara, Eiki| Yamane, Hiromichi| Tanimoto, Mitsune| Kiura, Katsuyuki| |
|---|---|
| 発行日 | 2013-01 |
| 出版物タイトル | Cancer Science |
| 巻 | 104巻 |
| 号 | 1号 |
| 資料タイプ | 学術雑誌論文 |
| 著者 | Rai, Kammei| Takigawa, Nagio| Ito, Sachio| Kashihara, Hiromi| Ichihara, Eiki| Yasuda, Tatsuji| Shimizu, Kenji| Tanimoto, Mitsune| Kiura, Katsuyuki| |
|---|---|
| 発行日 | 2011-09 |
| 出版物タイトル | Molecular Cancer Therapeutics |
| 巻 | 10巻 |
| 号 | 9号 |
| 資料タイプ | 学術雑誌論文 |
| 著者 | 頼 冠名| 瀧川 奈義夫| 伊藤 佐智夫| 柏原 宏美| 市原 英基| 保田 立二| 清水 憲二| 谷本 光音| 木浦 勝行| |
|---|---|
| 発行日 | 2012-12-03 |
| 出版物タイトル | 岡山医学会雑誌 |
| 巻 | 124巻 |
| 号 | 3号 |
| 資料タイプ | 学術雑誌論文 |